Investigation of Clinical Histopathologic Features and Metabolic Parameters of 18F-FDG PET/CT in Invasive Breast Carcinoma with a Micropapillary Component Mikropapiller Komponentli İnvazif Meme Kanserinde Klinik, Histopatolojik Özellikler ile 18F-FDG PET/BT Metabolik Parametrelerin İncelenmesi


AKGÜN E., Alçın G., Talu E. C. K., Çermik T. F., Akkurt T. S., Şen E., ...Daha Fazla

Molecular Imaging and Radionuclide Therapy, cilt.32, sa.3, ss.221-225, 2023 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 3
  • Basım Tarihi: 2023
  • Doi Numarası: 10.4274/mirt.galenos.2023.06078
  • Dergi Adı: Molecular Imaging and Radionuclide Therapy
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.221-225
  • Anahtar Kelimeler: 18F-FDG, micropapillary, breast cancer, PET/CT, SUVmax
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objectives: The aim of this study was to evaluate the correlation between clinical histopathologic features and micropapillary (MP) ratio with the maximum standardized uptake value (SUVmax) derived from18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in treatment naïve breast cancer. Methods: Twenty-nine patients diagnosed with breast cancer with a MP component who underwent PET/CT imaging before any local and/or systemic treatment were included in this retrospective study. All clinical histopathological features were recorded. SUVmax values were measured from18F-FDG PET images for primary tumors and metastatic axillary lymph nodes. Results: MP component percentage did not correlate with any clinical histopathological features except age. At early ages, the MP component ratio was significantly higher. Our results showed that there is no significant correlation between the SUVmax value and MP component percentage. Conclusion: A high SUVmax value is generally expected in aggressive malignancies. However, this assumption may not be valid for the MP subgroup, which has an aggressive course compared to other subgroups in breast cancer.